



PREVENTING OCCURRENCE OF TUBERCULOSIS IN PEOPLE LIVING WITH HIV

PREVENTING TB WITH A SAFE AND EFFECTIVE REGIMEN



Tuberculosis (TB) is the leading cause of death in people living with HIV worldwide, accounting for one-fourth of all HIV-related deaths. TB can be prevented with a 3- or 6-month regimen of a safe and effective treatment.

PROVIDING PREVENTIVE TREATMENT



The President's Emergency Plan for AIDS Relief (PEPFAR) has committed to provide at least one course of TB preventive treatment (TPT) to all people living with HIV (PLHIV) in care. By the end of 2022, over 10 million PLHIV received TPT globally through PEPFAR programs.

MEASURING THE IMPACT



PROTECT project will work to measure the impact of TPT on TB incidence and mortality. Additionally, some countries will evaluate the prevalence of isoniazid resistance and the added benefit of lifelong TPT (36 months).

OBTAINING DATA



The estimated sample size ranges from 20,000 to 200,000 PLHIV per country. This evaluation includes an analysis of secondary data that was recorded electronically in routine programmatic conditions. Outcomes will be adjusted for age, sex, antiretroviral therapy, CD4 cell count, viral suppression, and TPT regimen.

SHARING LESSONS LEARNED AND BEST PRACTICES



Findings will be shared with national stakeholders, affected communities, and global programs to help inform additional scale-up of TPT for PLHIV.



ABOUT PROTECT

The PROTECT Study is a three-year programmatic assessment that seeks to evaluate the impact of TPT across six countries—**Haiti, Kenya, Nigeria, Uganda, Ukraine, and Zimbabwe**—among PLHIV, using individual-level clinical data to measure the following outcomes:

- New TB diagnosis after TPT completion
- Mortality among PLHIV who completed TPT

Additional objectives:

- To evaluate the prevalence of isoniazid resistance among PLHIV
- To evaluate the effectiveness of isoniazid TPT in a setting with a high MDR TB burden
- To evaluate the effectiveness of 36-months (or lifelong TPT) as compared to 6 months of isoniazid treatment

Email inquires to PROTECT@cdcfoundation.org



PROGRAM PARTNERS

This project is being implemented by the CDC Foundation, in partnership with the U.S. Centers for Disease Control and Prevention (CDC), Emory University, CDC country offices, Ministries of Health and Implementing Partners [Eastern Deanery AIDS Relief Program (EDARP), Catholic Medical Mission Board (CMMB), Georgetown Global Health Nigeria (GGHN), Makerere University School of Public Health – Monitoring And Evaluation Technical Support (MakSPH-METS) and Zimbabwe Technical Assistance, Training and Education Center for Health (Zim-TTECH).

FUNDING PARTNERS

This project is funded by the Bill & Melinda Gates Foundation through the CDC Foundation.

